Rein Therapeutics (NASDAQ:RNTX) Releases Earnings Results, Beats Estimates By $0.17 EPS

Rein Therapeutics (NASDAQ:RNTX) announced its quarterly earnings results on Friday. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.17, Zacks reports.

Rein Therapeutics Stock Performance

Shares of RNTX stock traded up $0.02 on Friday, hitting $0.81. The company had a trading volume of 211,019 shares, compared to its average volume of 424,245. Rein Therapeutics has a twelve month low of $0.69 and a twelve month high of $2.18. The firm has a market cap of $68.95 million, a P/E ratio of -0.42 and a beta of 1.39. The stock’s 50-day moving average is $0.89 and its two-hundred day moving average is $1.14.

Institutional Trading of Rein Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP acquired a new stake in Rein Therapeutics during the 3rd quarter valued at approximately $35,000. HRT Financial LP bought a new stake in shares of Rein Therapeutics in the 4th quarter valued at $38,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Rein Therapeutics in the 2nd quarter valued at $68,000. Jane Street Group LLC acquired a new stake in shares of Rein Therapeutics during the fourth quarter worth $72,000. Finally, State Street Corp increased its position in shares of Rein Therapeutics by 374.3% during the fourth quarter. State Street Corp now owns 75,904 shares of the company’s stock worth $88,000 after buying an additional 59,900 shares during the period. 90.89% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

RNTX has been the topic of several research reports. Weiss Ratings upgraded Rein Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 3rd. Wall Street Zen upgraded shares of Rein Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. HC Wainwright reduced their target price on shares of Rein Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, June 1st. Finally, Maxim Group started coverage on shares of Rein Therapeutics in a research note on Monday, July 20th. They set a “buy” rating and a $4.00 price target for the company. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $6.00.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.